ATC Group: L02BB04 Enzalutamide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L02BB04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L02 Endocrine therapy
3 L02B Hormone antagonists and related agents
4 L02BB Anti-androgens
5 L02BB04

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.16 g

Active ingredients in L02BB04

Active Ingredient Description
Enzalutamide

Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression.

Related product monographs

Title Information Source Document Type  
XTANDI Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.